{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DDI+%28Drug-Drug+Interaction%29&page=2", "query": { "condition": "DDI (Drug-Drug Interaction)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DDI+%28Drug-Drug+Interaction%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T08:09:10.875Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02824042", "title": "Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medical Oncology" ], "interventions": [ { "name": "Anetumab ravtansine (BAY94-9343)", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2016-09-07", "completion_date": "2019-08-05", "has_results": false, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 5, "location_summary": "Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02824042" }, { "nct_id": "NCT04537715", "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "All Malignancies", "Advanced Malignancies", "Hematologic Malignancy", "Solid Tumor", "Follicular Lymphoma (FL)", "Non-Hodgkin Lymphoma (NHL)", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Epithelioid Sarcoma (ES)", "Synovial Sarcoma", "Renal Medullary Carcinoma", "Mesothelioma", "Rhabdoid Tumor" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-23", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 7, "location_summary": "Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537715" }, { "nct_id": "NCT02647086", "title": "Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-12", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Berlin", "state": "New Jersey" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02647086" }, { "nct_id": "NCT01082276", "title": "Rifampin Drug-Drug Interaction Study With Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male, Healthy Normal Subjects" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 20, "start_date": "2008-08", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082276" }, { "nct_id": "NCT00002096", "title": "A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cytomegalovirus Infections", "HIV Infections" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 3, "location_summary": "Irvine, California • Washington D.C., District of Columbia • Galveston, Texas", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002096" }, { "nct_id": "NCT00860275", "title": "Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "BMS-708163", "type": "DRUG" }, { "name": "BMS-708163 + Ketoconazole", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "BMS-708163 + Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2011-01-25", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860275" }, { "nct_id": "NCT07389525", "title": "Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms", "Genitourinary Cancer", "Thoracic Cancer", "Sarcoma", "Melanoma" ], "interventions": [ { "name": "ICI Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07389525" }, { "nct_id": "NCT00752843", "title": "A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "mifepristone + fluvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2008-09", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2012-02-17", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752843" }, { "nct_id": "NCT00741468", "title": "Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "Proellex", "type": "DRUG" }, { "name": "CYP1A2 probe", "type": "DRUG" }, { "name": "CYP2C9 probe", "type": "DRUG" }, { "name": "CYP2C19 probe", "type": "DRUG" }, { "name": "CYP2D6 probe", "type": "DRUG" }, { "name": "CYP3A4 probe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "48 Years", "sex": "FEMALE", "summary": "18 Years to 48 Years · Female only" }, "enrollment_count": 18, "start_date": "2008-07", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741468" }, { "nct_id": "NCT03555617", "title": "Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Inflammatory Bowel Disease" ], "interventions": [ { "name": "TD-1473", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2018-06-13", "completion_date": "2018-07-15", "has_results": false, "last_update_posted_date": "2021-01-14", "last_synced_at": "2026-07-24T08:09:10.875Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03555617" } ] }